Can reduction in resting heart rate be beneficial for patients?

Czech version

Authors: M. Souček
Authors‘ workplace: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in: Vnitř Lék 2007; 53(4): 401-403
Category: Reviews

Overview

The relationship between resting heart rate and mortality is well documented in healthy people and patients with hypertension, heart failure, non-fatal myocardial infarction, metabolic syndrome and in old people. Resting tachycardia also contributes to reduced life length and is an important independent predictor of cardiovascular morbidity and mortality [1]. It therefore seems reasonable to reduce both heart rate and myocardial oxygen consumption. Simple measurement of resting heart rate can provide useful prognostic information. The most common pharmacological treatments to control heart rate are beta-blockers or calcium channel blockers (verpamil, diltiazem). At present we have a new medicine that selectively inhibits If channels located in the sinoatrial node of the myocardium and reduces only heart rate.

Key words:
heart rate – hypertension – heart failure – cardiovascular mortality – pharmacological control of pulse rate

Sources

1. Purcell H. Heart rate as a target in ischaemic heart disease. Eur Heart J 1999; 1(Suppl H): H58-H63.

2. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-1482.

3. Sajadieh A, Nielsen OW, Rasmussen V et al. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004; 25: 363-370.

4. Levine HJ. Rest heart rate and life expectancy. J Am Cardiol 1997; 30: 1104-1106.

5. Schamroth L. An Introduction to Electrocardiography. 7th ed. Oxford (UK): Blackwell Scientific Publications; 1990.

6. Palatini P. Need for revision of the normal limits of resting heart rate. Hypertension 1999; 33: 622-625.

7. Kannel WB, Kannel C, Paffenbarger RS et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1484-1489.

8. Gillman MW, Kannel WB, Belanger A et al. Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 1993; 125: 1148-1154.

9. Kim JR, Kiefe CI, Liu K et al. Heart rate and subsequent blood pressure in young adults. The CARDIA Study. Hypertension 1999; 33: 640-646.

10. Benetos A, Rudnichi A, Tomas F et al. Influence of heart rate on mortality in a French population. Role of age, gender, and blood pressure. Hypertension 1999; 33: 44-52.

11. Palatini P, Casiglia E, Julius S et al. High heart rate. A risk factor for cardiovascular death in elderly men. Arch Intern Med 1999; 159: 1404-1410.

12. Zuanetti G, Mantini L, Hernandez-Bernal F et al. Relevance of heart rate as a prognostic factor in patients with acute myoardial infarction: insights from the GISSI-2 study. Eur Heart J 1998; 19(Suppl F): F19-F26.

13. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute long-term myocardial intervention trials. Am J Cardiol 1986; 57: 43F-49F.

14. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-392.

15. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial - DAVIT II). Am J Cardiol 1990; 66: 779-785.

16. Borer JS, Fox K, Jaillon P et al. Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomised, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-823.